The global G-protein coupled receptors market size was estimated at USD 2.60 billion in 2018 and is projected to expand further at a CAGR of 6.7% from 2019 to 2026. GPCRs respond to a wide range of external stimulus and a part of several disease etiologies. Wide application of techniques, such as High-Throughput Screening (HTS), combinatorial chemistry, and medicinal chemistry, has led to the identification of ligands that modulate the target's activity.
This, in turn, has resulted in the effective identification of pharmaceutically relevant drug candidates, which drives the adoption of these receptors in the drug discovery processes. Presence of large number approved drugs and drugs under clinical and preclinical studies, which target these receptors, boost the demand for GPCR screening assays in drug development. Moreover, an increasing number of allosteric modulators, biological drugs, and biased agonists that target these receptors accelerate the demand for associated assays.
Advancements in the computational approaches to streamline receptor structure contribute to the development ofeffective drug discovery methods. Researchers from the University of Southern California, the Skolkovo Institute of Science & Technology, and the Moscow Institute of Physics & Technology designed a thermally stable GPCR by a computational method for the formulation of new drugs.
Companies in the market focus more on research to explore the novel biological functions of the approved and withdrawn drug candidates, so that these can be used for other indications as well. A research based on custom-designed oligonucleotide GPCR chip by Arena Pharmaceuticals has identified a relative expression of more than seven hundred receptors of high therapeutic importance. This research would be further utilized for the discovery of small molecules.
The availability of an extensive range of cell lines for the assays resulted in the largest revenue share of cell lines in 2018. Cell lines play a major role in the cellular impedance assays for the detection of GPCR targets thus attributing to the estimated revenue share. Detection kits have gained popularity in recent years, as they are an easy-to-use, robust, and highly sensitive products to evaluate the activity through different pathways. Moreover, the advent of new detection strategies based on nonlabelled systems, such as resonance wave-guide grating or impedance-based sensors, is anticipated to support the growth of the segment.
Owing to the fact that cyclic Adenosine Monophosphate (cAMP) is an important intracellular second messenger in GPCR signal transduction, cAMP assays accounted for the largest revenue share in 2018. Presence of a broad product portfolio, in terms of reagent kits for the measurement of the cAMP messenger levels, is further driving the segment. Calcium functional assays segment is expected to witness the fastest CAGR from 2019 to 2026 on account of the advantages associated with the use of calcium flux assays, such as high sensitivity, ease in the estimation of calcium flux, and user configurability.
A substantial number of applications are associated with G-protein coupled receptor activity for the treatment of several disorders. Majority of tumor angiogenesis and immunotherapy related detections are associated with GPCR activity. The ubiquitously expressed protein is involved in intercellular communication that paves the path for the development of potential therapeutics.
Implementation of GPCR assays in cancer research generates substantial revenue. Several studies have proved that the GPCR activity reveals the tumor proliferation, invasiveness, angiogenesis, metastasis, and drug resistance in cancer patients. As per the research, each type of cancer cell/tumor is found to express a common set of GPCR. It has also been observed that >150 different GPCRs are expressed by some types of cell, out of which one is expressed at a comparatively high level.
This pronounces the biomarker-based research in the sector thus leading to development of lead candidate targeting GPCRs. The role of this receptor has evolved in the inflammation research area over recent years. G-protein coupled receptor kinases regulate the signaling pathways, such as nuclear factor κ-B signaling pathway, which is related to different inflammatory processes. Thus, these signaling pathways act as a potential therapeutic target in various inflammatory diseases.
North America led the global G-protein coupled receptors market in 2018 due to the strategic investments in cancer research, approval of GPCR-targeted drugs, and increased focus on drug discovery & development activities. In November 2017, 134 GPCR targets for drugs were approved in U.S. or European Union and 128 targets were listed in the FDA orange book. Asia Pacific is anticipated to be the fastest-growing regional market over the forecast years due to the presence of several emerging companies, such as Sosei Heptares, HD Biosciences Co., Ltd., and NB Health Laboratory. The number of growth initiatives undertaken by the companies to improve their market presence drives regional growth.
Some key participants operating in the GPCRs market include Thermo Fisher Scientific, Inc.; Eurofins Scientific; QIAGEN; WuXi AppTec(HD Biosciences Co. Ltd); Promega Corporation; Abcam plc; Perkin Elmer Inc.(Cisbio Bioassays); Enzo Biochem Inc.; Merck KGaA; and Becton-Dickinson and Company.
Mergers, acquisitions, and licensing deals for the R&D activities are the key strategies undertaken by these companies to maintain their market presence. Moreover, they are integrating automation and innovative technologies with drug development screening procedures to improve their capabilities in therapeutic production.
Attribute |
Details |
Base year for estimation |
2018 |
Actual estimates/Historical data |
2015 - 2017 |
Forecast period |
2019 - 2026 |
Market representation |
Revenue in USD Million and CAGR from 2019 to 2026 |
Regional scope |
North America, Europe, Asia Pacific, Latin America, and MEA |
Country scope |
U.S., Canada, Germany, U.K., China, India, Japan, Brazil, and South Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
15% free customization scope (equivalent to 5 analyst working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global G-protein coupled receptors market report on the basis of product, assay type, application, and region:
Product Outlook (Revenue, USD Million, 2015 - 2026)
Cell Lines
Detection Kits
Cell Culture Reagents
Ligands
Assay Type Outlook (Revenue, USD Million, 2015 - 2026)
cAMP Functional Assays
Calcium Functional Assays
β-Arrestin Functional Assays
Radioligand Binding and GTPγS Functional Assays
Internalization Assays
Trafficking Assays
Other Assays
Application Outlook (Revenue, USD Million, 2015 - 2026)
Cancer Research
CNS Research
Metabolic Research
Cardiovascular Research
Respiratory Research
Inflammation Research
Other Application
Regional Outlook (Revenue, USD Million, 2015 - 2026)
North America
U.S.
Canada
Europe
Germany
U.K.
Asia Pacific
China
India
Japan
Latin America
Brazil
Middle East and Africa (MEA)
South Africa
b. The global G-protein coupled receptors market size was estimated at USD 2.8 billion in 2019 and is expected to reach USD 3.0 billion in 2020.
b. The global G-protein coupled receptors market is expected to grow at a compound annual growth rate of 6.7% from 2019 to 2026 to reach USD 4.4 billion by 2026.
b. Some key players operating in the G-protein coupled receptors market include Thermo Fisher Scientific, Inc.; Eurofins Scientific; QIAGEN; WuXi AppTec(HD Biosciences Co. Ltd); Promega Corporation; Abcam plc; Perkin Elmer Inc.(Cisbio Bioassays); Enzo Biochem Inc.; Merck KGaA; and Becton-Dickinson and Company.
b. Some of the market opportunities for market growth include the advancements in the understanding of GPCR biology in oncology for the development of combined therapies and technological advancements in the market.
b. Key factors that are driving the market growth include growing demand for GPCR assays in drug discovery studies; wide application of GPCRs in the treatment for various medical conditions; the rising number of initiatives by government and key players.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.